Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.

Bibliographic Details
Main Authors: Peterfy, C, Emery, P, Genovese, M, Keystone, E, Taylor, P, Berclaz, P, DiCarlo, J, Lee, C, Schlichting, D, Beattie, S, Luchi, M, Macias, W
Format: Conference item
Published: 2012

Similar Items